The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
KADMON HLDGS INC COM 48283N106 126 30,000 SH   SOLE   0 30,000 0
EKSO BIONICS HLDGS INC COM 282644301 2,192 774,400 SH   SOLE   0 774,400 0
BELLEROPHON THERAPEUTICS INC COM NEW 078771300 6,064 553,250 SH   SOLE   0 553,250 0
TRACON PHARMACEUTICALS INC COM NEW 89237H209 31 18,107 SH   SOLE   0 18,107 0
CORVUS PHARMACEUTICALS INC COM 221015100 80 38,010 SH   SOLE   0 38,010 0
SCYNEXIS INC COM 811292101 67 86,075 SH   SOLE   0 86,075 0